Hanall Biopharma undervalued at 25% of Immunovant’s market cap, broker says
AI Summary- Hyundai Motor Securities retained a buy rating and named Hanall Biopharma its sector top pick.
- Hanall Biopharma’s 2.873 trillion-won market cap equals 25% of Immunovant’s roughly 12 trillion won.
- IMVT-1402’s final difficult-to-treat rheumatoid arthritis results are due in the second half of this year.